Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · see citing works

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,442 · see citing works

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,313 · see citing works

Epidermal growth factor-related peptides and their receptors in human malignancies.

Salomon, D., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical reviews in oncology/hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,860 · see citing works

Epidermal growth factor receptor (EGFR) signaling in cancer

Normanno, N., Luca, A. D., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., Carotenuto, A., Feo, G. D., Caponigro, F., & Salomon, D. S. (2005) · Gene · doi:10.1016/j.gene.2005.10.018 · Cited by 2,035 · see citing works

A Lentiviral RNAi Library for Human and Mouse Genes Applied to an Arrayed Viral High-Content Screen

Moffat, J., Grueneberg, D. A., Yang, X., Kim, S. Y., Kloepfer, A. M., Hinkle, G., Piqani, B., Eisenhaure, T., Luo, B., Grenier, J. K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.01.040 · Cited by 1,803 · see citing works

USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER2

Lamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199 · see citing works

A Hierarchical Network of Interreceptor Interactions Determines Signal Transduction by Neu Differentiation Factor/Neuregulin and Epidermal Growth Factor

Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,039 · see citing works

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Böesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1328 · Cited by 1,036 · see citing works

ErbB Receptors: Directing Key Signaling Networks Throughout Life

Holbro, T., & Hynes, N. E. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121440 · Cited by 642 · see citing works

A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy

Lee-Hoeflich, S. T., Crocker, L., Yao, E. S., Pham, T. Q., Munroe, X., Hoeflich, K. P., Sliwkowski, M. X., & Stern, H. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0380 · Cited by 632 · see citing works

The Crystal Structure of a Truncated ErbB2 Ectodomain Reveals an Active Conformation, Poised to Interact with Other ErbB Receptors

Garrett, T., McKern, N. M., Lou, M., ELLEMAN, T. C., Adams, T. E., Lovrecz, G. O., Kofler, M., Jorissen, R. N., Nice, E. C., Burgess, A. W., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00048-0 · Cited by 614 · see citing works

Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents

Sharma, S. V., Haber, D. A., & Settleman, J. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2820 · Cited by 585 · see citing works

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

Shi, F., Telesco, S., Liu, Y., Radhakrishnan, R., & Lemmon, M. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002753107 · Cited by 469 · see citing works

Oncogene addiction: setting the stage for molecularly targeted cancer therapyPreprint

Sharma, S. V., & Settleman, J. E. (2007) · Genes & Development · doi:10.1101/gad.1609907 · Cited by 442 · see citing works

Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

McDermott, U., Iafrate, A. J., Gray, N. S., Shioda, T., Classon, M., Maheswaran, S., Zhou, W., Choi, H. G., Smith, S. L., Dowell, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6186 · Cited by 397 · see citing works

Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases

MEDINA, P., & Goodin, S. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.008 · Cited by 377 · see citing works

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

McDermott, U., Sharma, S. V., Dowell, L., Greninger, P., Montagut, C. O., Lamb, J. A., Archibald, H., Raudales, R., Tam, A., Lee, D. W., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707498104 · Cited by 352 · see citing works

Serum insulin-like growth factor-I and breast cancer

Toniolo, P. G., Bruning, P. F., Akhmedkhanov, A., Bonfrèr, J. M. G., Koenig, K. L., Lukanova, A., Shore, R. E., & Zeleniuch‐Jacquotte, A. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001201)88:5 · Cited by 341 · see citing works

Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

Agulnik, M., Cohen, E. E. W., Cohen, R. B., Chen, E. X., Vokes, E. E., Hotte, S. J., Winquist, E., Laurie, S. A., Hayes, D. N., Dancey, J. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8612 · Cited by 262 · see citing works

An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells

Sheng, Q., Liu, X., FLEMING, E. M., Yuan, K., Piao, H., Chen, J., MOUSTAFA, Z. R., Thomas, R. K., Greulich, H. E., Schinzel, A. C., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.047 · Cited by 234 · see citing works

High-affinity Human Antibodies from Phage-displayed Synthetic Fab Libraries with a Single Framework Scaffold

Lee, C. V., Liang, W., Dennis, M. S., Eigenbrot, C. W., Sidhu, S. S., & Fuh, G. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.05.051 · Cited by 228 · see citing works

MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Jin, H., Yang, R., Zheng, Z., Romero, M., Ross, J., Bou-Reslan, H., Carano, R. A. D., Kasman, I. M., Mai, E., Young, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5960 · Cited by 220 · see citing works

Transformation of NIH 3T3 Cells by HER3 or HER4 Receptors Requires the Presence of HER1 or HER2

Zhang, K., Sun, J., Liu, N., Wen, D., Chang, D., Thomason, A., & Yoshinaga, S. K. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.7.3884 · Cited by 207 · see citing works

Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver

Amin, D. N., Sergina, N. V., Ahuja, D., McMahon, M., Blair, J. A., Wang, D., Hann, B. C., Koch, K. M., Shokat, K. M., & Moasser, M. M. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000389 · Cited by 175 · see citing works

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story

Sequist, L. V. D., & Lynch, T. J. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.59.090506.202405 · Cited by 156 · see citing works

ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface

Berger, M. B., Mendrola, J. M., & Lemmon, M. A. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.06.014 · Cited by 150 · see citing works

High-resolution analysis of chromosome rearrangements on 8p in breast, colon and pancreatic cancer reveals a complex pattern of loss, gain and translocation

Pole, J. C. M., Courtay, C., García, M. J., Blood, K. A., Cooke, S., Alsop, A. E., Tse, D. M. L., Caldas, C., & Edwards, P. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209570 · Cited by 142 · see citing works

Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy.

Weinstein, I. B., Begemann, M., Zhou, P., Han, E. K.-H., Sgambato, A., Doki, Y., Arber, N., Ciaparrone, M., & Yamamoto, H. (1997) · PubMed · Cited by 125 · see citing works

Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers

Yonesaka, K., Zejnullahu, K., Lindeman, N. I., Homes, A. J., Jackman, D. M., Zhao, F., Rogers, A. M., Johnson, B. E., & Janne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0957 · Cited by 120 · see citing works

The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma

O‐charoenrat, P. (2002) · Oral Oncology · doi:10.1016/s1368-8375(02)00029-5 · Cited by 108 · see citing works

γ-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175

Schaefer, G., Fitzpatrick, V. D., & Sliwkowski, M. X. (1997) · Oncogene · doi:10.1038/sj.onc.1201317 · Cited by 104 · see citing works

A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies

Burris, H. A., Taylor, C. W., Jones, S. F., Koch, K. M., Versola, M., Arya, N., Fleming, R. A., Smith, D. A., Pandite, L. N., Spector, N. L., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0369 · Cited by 99 · see citing works

Erlotinib: Small-molecule targeted therapy in the treatmentof non-small-cell lung cancer

Smith, J. A. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.10.014 · Cited by 98 · see citing works

Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors

McDermott, U., Ames, R. Y., Iafrate, A. J., Maheswaran, S., Stubbs, H., Greninger, P., McCutcheon, K., Milano, R. J., Tam, A., Lee, D. W., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4327 · Cited by 96 · see citing works

A Recurrent Chromosome Breakpoint in Breast Cancer at the NRG1 / Neuregulin 1 / Heregulin Gene

Huang, H.-E., Chin, S., Ginestier, C., Bardou, V., Adélaı̈de, J., Iyer, N. G., García, M. J., Pole, J. C. M., Callagy, G. M., Hewitt, S. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1762 · Cited by 92 · see citing works

The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene

Chua, Y. W., Ito, Y., Pole, J. C. M., Newman, S., Chin, S. F., Stein, R. C., Ellis, I. O., Caldas, C., O'Hare, M. J., Murrell, A., et al. (2009) · Oncogene · doi:10.1038/onc.2009.259 · Cited by 83 · see citing works

The ErbB kinase domain: Structural perspectives into kinase activation and inhibition

Bose, R., & Zhang, X. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.07.031 · Cited by 78 · see citing works

Phase I Study of Lapatinib in Combination With Chemoradiation in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Harrington, K. J., El‐Hariry, I. A., Holford, C. S., Lusinchi, A., Nutting, C. M., Rosine, D., Tanay, M. A., Deutsch, É., Matthews, J., D'Ambrosio, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5349 · Cited by 78 · see citing works

Efficacy of ligand-based targeting for the EGF system in cancer.

Yotsumoto, F., Sanui, A., Fukami, T., Shirota, K., Horiuchi, S., Tsujioka, H., Yoshizato, T., Kuroki, M., & Miyamoto, S. (2009) · PubMed · Cited by 28 · see citing works

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134 · see citing works

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048 · see citing works

Relief of Feedback Inhibition of <i>HER3</i> Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in <i>BRAF</i> -Mutant Thyroid Carcinomas

Montero-Conde, C., Ruiz-Llorente, S., Dominguez, J. M., Knauf, J. A., Viale, A., Sherman, E. J., Ryder, M., Ghossein, R. A., Rosen, N., & Fagin, J. A. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0531 · Cited by 382 · see citing works

Spatial regulation of receptor tyrosine kinases in development and cancer

Casaletto, J. B., & McClatchey, A. I. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3277 · Cited by 362 · see citing works

Oncogenic ERBB3 mutations in human cancers.

Jaiswal, B. S., Kljavin, N. M., Stawiski, E. W., Chan, E., Parikh, C., Durinck, S., Chaudhuri, S., Pujara, K., Guillory, J., Edgar, K. A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.012 · Cited by 350 · see citing works

The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation

Raha, D., Wilson, T. R., Peng, J., Peterson, D., Yue, P., Evangelista, M., Wilson, C., Merchant, M., & Settleman, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3456 · Cited by 307 · see citing works

Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer

Zhang, Z., Karthaus, W. R., Lee, Y. S., Gao, V. R., Wu, C., Russo, J. W., Liu, M., Mota, J. M., Abida, W. M., Linton, E. L., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.005 · Cited by 259 · see citing works

Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy

Lee, J., Liu, Z., Sa, J. K., Shin, S. H., Wang, J., Bordyuh, M., Cho, H. J., Elliott, O., Chu, T., Choi, S. W., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0209-6 · Cited by 204 · see citing works

Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer

Byeon, H. K., Ku, M., & Yang, J. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0202-2 · Cited by 199 · see citing works

Integrated genomic profiling expands clinical options for patients with cancer

Beaubier, N. T., Bontrager, M., Huether, R., Igartua, C., Lau, D., Tell, R. W., Bobe, A. M., Bush, S. J., Chang, A. L., Hoskinson, D. C., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0259-z · Cited by 187 · see citing works

Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy

Chen, K., Yang, D., Li, X., Sun, B., Song, F., Cao, W., Brat, D. J., Gao, Z., Li, H., Liang, H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422640112 · Cited by 173 · see citing works

Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling

Boeck, A. D., Pauwels, P., Hensen, K., Rummens, J., Westbroek, W., Hendrix, A., Maynard, D., Denys, H. G., Lambein, K., Braems, G., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301393 · Cited by 169 · see citing works

NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents

Laskin, J. J., Liu, S. V., Tolba, K. A., Heining, C., Schlenk, R. F., Cheema, P. K., Cadranel, J. L., Jones, M. R., Drilon, A. E. D. C., Cseh, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2335 · Cited by 167 · see citing works

Mechanobiology in the development, maintenance, and degeneration of articular cartilage.

Beaupré, G. S., Stevens, S. S., & Carter, D. R. P. (2000) · PubMed · Cited by 154 · see citing works

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms

Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 152 · see citing works

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models

Xia, W., Petricoin, E., Zhao, S., Liu, L.-H., Osada, T., Cheng, Q., Wulfkuhle, J. D., Gwin, W. R., Yang, X., Gallagher, R. I., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3480 · Cited by 143 · see citing works

Activation of Multiple ERBB Family Receptors Mediates Glioblastoma Cancer Stem-like Cell Resistance to EGFR-Targeted Inhibition

Clark, P. A., Iida, M., Treisman, D. M., Kalluri, H. S. G., Ezhilan, S., Zorniak, M., Wheeler, D. L., & Kuo, J. S. (2012) · Neoplasia · doi:10.1596/neo.12432 · Cited by 141 · see citing works

Understanding the biology of HER3 receptor as a therapeutic target in human cancer

Lyu, H., Han, A., Polsdofer, E., Liu, S., & Liu, B. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.05.010 · Cited by 125 · see citing works

Epithelial-to-Mesenchymal Transition Rewires the Molecular Path to PI3K-Dependent Proliferation

Salt, M. B., Bandyopadhyay, S., & McCormick, F. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0520 · Cited by 124 · see citing works

An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin

Garner, A. P., Bialucha, C. U., Sprague, E. R., Garrett, J. T., Sheng, Q., Li, S., Sineshchekova, O., Saxena, P., Sutton, C. R., Chen, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1198 · Cited by 123 · see citing works

ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer

Deblois, G., Smith, H. W., Tam, I. S., Gravel, S., Caron, M., Savage, P., Labbé, D. P., Bégin, L. R., Tremblay, M. L., Park, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms12156 · Cited by 120 · see citing works

miR-148a-3p represses proliferation and EMT by establishing regulatory circuits between ERBB3/AKT2/c-myc and DNMT1 in bladder cancer

Wang, X., Liang, Z. C., Xu, X., Li, J., Zhu, Y., Meng, S., Li, S., Wang, S., Xie, B., Ji, A., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.373 · Cited by 120 · see citing works

Thirty Years of HER3: From Basic Biology to Therapeutic Interventions

Haikala, H. M., & Janne, P. A. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4465 · Cited by 117 · see citing works

An Arntl2-Driven Secretome Enables Lung Adenocarcinoma Metastatic Self-Sufficiency

Brady Jennifer, J., Chuang, C.-H., Greenside, P., Rogers, Z. N., Murray, C. W., Caswell, D. R., Hartmann, U., Connolly, A. J., Sweet-Cordero, A., Kundaje, A. B., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.003 · Cited by 112 · see citing works

Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade

Geuijen, C. A. W., Nardis, C. D., Maussang, D., Rovers, E., Gallenne, T., Hendriks, L. J. A., Visser, T., Nijhuis, R., Logtenberg, T., de Kruif, J., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.003 · Cited by 108 · see citing works

Computational Modeling of ERBB2 -Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors

Kirouac, D. C., Du, J. Y., Lahdenranta, J., Overland, R. P., Yarar, D., Paragas, V. B., Pace, E. A., McDonagh, C. F., Nielsen, U. B., & Onsum, M. D. (2013) · Science Signaling · doi:10.1126/scisignal.2004008 · Cited by 105 · see citing works

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

Fayette, J., Wirth, L. J., Oprean, C. M., Udrea, A. A., Jimeno, A., Rischin, D., Nutting, C. M., Harari, P. M., Csőszi, T., Cernea, D. M., et al. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00232 · Cited by 103 · see citing works

2D protrusion but not motility predicts growth factor–induced cancer cell migration in 3D collagen

Meyer, A. S., Hughes, S. K., Kay, J. E., Castillo, A., Wells, A. H., Gertler, F. B., & Lauffenburger, D. A. (2012) · The Journal of Cell Biology · doi:10.1083/jcb.201201003 · Cited by 94 · see citing works

Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer

Fernandez‐Cuesta, L., & Thomas, R. K. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0854 · Cited by 94 · see citing works

Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors

LoRusso, P. M., Janne, P. A., de Oliveira, M. R., Rizvi, N. A., Malburg, L., Keedy, V. L., Yee, L., Copigneaux, C., Hettmann, T., Wu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3051 · Cited by 92 · see citing works

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

Yonesaka, K., Hirotani, K., Kawakami, H., Takeda, M., Kaneda, H., Sakai, K., Okamoto, I., Nishio, K., Janne, P. A., & Nakagawa, K. (2015) · Oncogene · doi:10.1038/onc.2015.142 · Cited by 90 · see citing works

An Engineered Bivalent Neuregulin Protects Against Doxorubicin-Induced Cardiotoxicity With Reduced Proneoplastic Potential

Jay, S. M., Murthy, A. C., Hawkins, J. F., Wortzel, J. R., Steinhauser, M. L., Alvarez, L. M., Gannon, J., MacRae, C. A., Griffith, L. G., & Lee, R. T. (2013) · Circulation · doi:10.1161/circulationaha.113.002203 · Cited by 89 · see citing works

Targeted therapies for squamous cell carcinoma of the head and neck: Current knowledge and future directions

Schmitz, S., Ang, K. K., Vermorken, J. B., Haddad, R. I., Suarez, C. M., Wolf, G. T., Hamoir, M., & Machiels, J.-P. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.09.007 · Cited by 88 · see citing works

Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies

Leto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87 · see citing works

Blocking NRG1 and Other Ligand-Mediated Her4 Signaling Enhances the Magnitude and Duration of the Chemotherapeutic Response of Non–Small Cell Lung Cancer

Hegde, G. V., de la Cruz, C. C., Chiu, C., Alag, N., Schaefer, G., Crocker, L., Ross, S., Goldenberg, D., Merchant, M. A., Tien, J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004438 · Cited by 84 · see citing works

ΔNp63 in squamous cell carcinoma: defining the oncogenic routes affecting epigenetic landscape and tumour microenvironment

Gatti, V., Fierro, C., Annicchiarico‐Petruzzelli, M., Melino, G., & Peschiaroli, A. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12473 · Cited by 83 · see citing works

Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions

Gay, N. D., Wang, Y., Beadling, C., Warrick, A., Neff, T. L., Corless, C. L., & Tolba, K. A. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.025 · Cited by 79 · see citing works

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

Meulendijks, D., Jacob, W., Martinez-Garcia, M., Taus, A., Lolkema, M. P., Voest, E. E., Langenberg, M. H. G., Fleitas Kanonnikoff, T., Cervantes, A., De Jonge, M. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1683 · Cited by 73 · see citing works

Development of Effective Therapeutics Targeting HER3 for Cancer Treatment

Liu, X., Liu, S., Lyu, H., Riker, A. I., Zhang, Y., & Liu, B. (2019) · Biological Procedures Online · doi:10.1186/s12575-019-0093-1 · Cited by 72 · see citing works

High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck

Shames, D. S., Carbon, J. G., Kim, W., Jubb, A. M., Kozlowski, C., Januario, T., Do, A., Fu, L. L., Xiao, Y., Raja, R. G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056765 · Cited by 71 · see citing works

A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer

Mota, J. M., Collier, K. A., Costa, R. L. B., Taxter, T., Kalyan, A., Leite, C. A., Chae, Y. K., Giles, F. J., & Carneiro, B. A. (2017) · Oncotarget · doi:10.18632/oncotarget.18467 · Cited by 70 · see citing works

MiR-125a-3p Regulates Glioma Apoptosis and Invasion by Regulating Nrg1

Yin, F., Zhang, J. N., Wang, S. W., Zhou, C. H., Zhao, M., Fan, W. H., Fan, M., & Liu, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116759 · Cited by 69 · see citing works

Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib

Younes, M., Wu, Z., Dupouy, S., Mansuet‐Lupo, A., Mourra, N., Takahashi, T., Fléjou, J. F., Trédaniel, J., Régnard, J. F., Damotte, D., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1633 · Cited by 65 · see citing works

Locally advanced head and neck squamous cell cancer: treatment choice based on risk factors and optimizing drug prescription

Braña, I., & Siu, L. L. (2012) · Annals of Oncology · doi:10.1093/annonc/mds322 · Cited by 65 · see citing works

HER3, serious partner in crime

Kol, A., van Scheltinga, A. G. T. T., Timmer‐Bosscha, H., Lamberts, L. E., Bensch, F., de Vries, E. G. E., & Schroder, C. P. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.01.005 · Cited by 61 · see citing works

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

Juric, D., Dienstmann, R., Cervantes, A., Hidalgo, M., Messersmith, W., Blumenschein, G. R., Tabernero, J., Roda, D., Calles, A., Jimeno, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2412 · Cited by 59 · see citing works

ERBB 3 ( HER 3) is a key sensor in the regulation of ERBB ‐mediated signaling in both low and high ERBB 2 ( HER 2) expressing cancer cells

Choi, B., Fan, X., Deng, H., Zhang, N., & An, Z. (2012) · Cancer Medicine · doi:10.1002/cam4.10 · Cited by 57 · see citing works

ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models

Zhang, L., Castanaro, C., Luan, B., Yang, K., Fan, L., Fairhurst, J. L., Rafique, A., Potocky, T. B., Shan, J., Delfino, F. J., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1033 · Cited by 56 · see citing works

Biomarkers of drugs targeting HER ‐family signalling in cancer

Montemurro, F., & Scaltriti, M. (2013) · The Journal of Pathology · doi:10.1002/path.4269 · Cited by 54 · see citing works

Advances in Targeting HER3 as an Anticancer Therapy

Jiang, N., Saba, N. F., & Chen, Z. G. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/817304 · Cited by 53 · see citing works

Dpp-induced Egfr signaling triggers postembryonic wing development in Drosophila

Paul, L., Wang, S., Manivannan, S., Bonanno, L. N., Lewis, S., Austin, C. L., & Simcox, A. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217538110 · Cited by 51 · see citing works

Neuregulin-1 (Nrg1) signaling has a preventive role and is altered in the frontal cortex under the pathological conditions of Alzheimer's disease

Jiang, Q., Chen, S., Hu, C., Huang, P., Shen, H., & Zhao, W. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5542 · Cited by 49 · see citing works

Ginsenoside Rd enhances blood-brain barrier integrity after cerebral ischemia/reperfusion by alleviating endothelial cells ferroptosis via activation of NRG1/ErbB4-mediated PI3K/Akt/mTOR signaling pathway

Hu, S., Fei, Y., Jin, C., Yao, J., Ding, H., Wang, J., & Liu, C. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109929 · Cited by 49 · see citing works

Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3

Rau, A., Lieb, W. S., Seifert, O., Honer, J., Birnstock, D., Richter, F., Aschmoneit, N., Olayioye, M. A., & Kontermann, R. E. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1095 · Cited by 49 · see citing works

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression

Schwarz, L. J., Hutchinson, K. E., Rexer, B. N., Estrada, M. V., Ericsson, P. I. G., Sanders, M. E., Dugger, T. C., Formisano, L., Zotano, Á. G., Red-Brewer, M., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx065 · Cited by 47 · see citing works

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck

Jimeno, A., Machiels, J., Wirth, L. J., Specenier, P. M., Seiwert, T. Y., Mardjuadi, F. I., Wang, X., Kapp, A. V., Royer‐Joo, S., Penuel, E. M., et al. (2016) · Cancer · doi:10.1002/cncr.30256 · Cited by 45 · see citing works

A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors

Gan, H. K., Millward, M., Jalving, M., Garrido‐Laguna, I., Lickliter, J. D., Schellens, J. H. M., Lolkema, M. P., van Herpen, C. M. L., Hug, B. A., Tang, L., et al. (2021) · The Oncologist · doi:10.1002/onco.13860 · Cited by 45 · see citing works

YAP1 maintains active chromatin state in head and neck squamous cell carcinomas that promotes tumorigenesis through cooperation with BRD4

Chen, N., Golczer, G., Ghose, S., Lin, B., Langenbucher, A., Webb, J., Bhanot, H., Abt, N. B., Lin, D. T., Varvares, M. A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110970 · Cited by 45 · see citing works

Neuregulin 1-HER axis as a key mediator of hyperglycemic memory effects in breast cancer

Park, J., Sarode, V. R., Euhus, D., Kittler, R., & Scherer, P. E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214400109 · Cited by 44 · see citing works

Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and Breast Cancer Cell Motility via Hypoxia-Inducible Factor 1α

López‐Haber, C., Barrio‐Real, L., Casado‐Medrano, V., & Kazanietz, M. G. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00180-16 · Cited by 43 · see citing works

Overexpression of NRG1 promotes progression of gastric cancer by regulating the self-renewal of cancer stem cells

Han, M., Kim, H., Shin, D., Hwang, S.-H., Kang, C., & Oh, S. (2014) · Journal of Gastroenterology · doi:10.1007/s00535-014-1008-1 · Cited by 41 · see citing works

LUZ-Y, a Novel Platform for the Mammalian Cell Production of Full-length IgG-bispecific Antibodies

Wranik, B. J., Christensen, E., Schaefer, G., Jackman, J. K., Vendel, A. C., & Eaton, D. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.397869 · Cited by 40 · see citing works

Heregulin induces resistance to lapatinib‐mediated growth inhibition of HER 2‐amplified cancer cells

Sato, Y., Yashiro, M., & Takakura, N. (2013) · Cancer Science · doi:10.1111/cas.12290 · Cited by 40 · see citing works

Overcoming resistance to HER2 inhibitors through state-specific kinase binding

Novotny, C. J., Pollari, S., Park, J. H., Lemmon, M. A., Shen, W., & Shokat, K. M. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2171 · Cited by 40 · see citing works

Downregulation of HER3 by a Novel Antisense Oligonucleotide, EZN-3920, Improves the Antitumor Activity of EGFR and HER2 Tyrosine Kinase Inhibitors in Animal Models

Wu, Y., Zhang, Y., Wang, M., Li, Q., Qu, Z., Shi, V., Kraft, P., Kim, S. H., Gao, Y. J., Pak, J., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0838 · Cited by 39 · see citing works

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

Meulendijks, D., Jacob, W., Voest, E. E., Mau‐Sørensen, M., Martinez‐García, M., Taus, Á., Fleitas, T., Cervantes, A. M. R., Lolkema, M. P., Langenberg, M. H. G., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0812 · Cited by 39 · see citing works

Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1–Mediated Lung Cancer

Shin, D. H., Jo, J. Y., & Han, J. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1178 · Cited by 39 · see citing works

Neuregulin 1 Enhances Cell Adhesion Molecule L1 Expression in Human Glioma Cells and Promotes Their Migration as a Function of Malignancy

Zhao, W., & Schachner, M. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182863dc5 · Cited by 38 · see citing works

Involvement of Heregulin/HER3 in the Primary Culture of Human Urothelial Cancer

Okuyama, H., Yoshida, T., Endo, H., Nakayama, M., Nonomura, N., Nishimura, K., & Inoue, M. (2013) · The Journal of Urology · doi:10.1016/j.juro.2012.12.106 · Cited by 38 · see citing works

Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma

Zhou, J. R., Wu, Z., Zhang, Z., Goss, L. B., McFarland, J. M., Nagaraja, A. K., Xie, Y., Gu, S. S., Peng, K., Zeng, Y., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-323276 · Cited by 38 · see citing works

Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression

Kotani, H., Ebi, H., Kitai, H., Nanjo, S., Kita, K., Huynh, T. G., Ooi, A., Faber, A. C., Mino-Kenudson, M. A., & Yano, S. (2015) · Oncogene · doi:10.1038/onc.2015.426 · Cited by 37 · see citing works

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Reynolds, K. L., Bedard, P. L., Lee, S., Lin, C., Tabernero, J. M., Alsina, M., Cohen, E. E. W., Baselga, J. M., Blumenschein, G. R., Graham, D. M., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3641-6 · Cited by 37 · see citing works

Targeting HER (ERBB) signaling in head and neck cancer: An essential update

Zhang, J., Saba, N. F., Chen, G. Z., & Shin, D. M. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.07.001 · Cited by 36 · see citing works

Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients

Yun, S., Koh, J., Nam, S. K., Park, J. O., Lee, S. M., Lee, K., Lee, K. S., Ahn, S.-H., Park, D. J., Kim, H., et al. (2017) · Gastric Cancer · doi:10.1007/s10120-017-0732-7 · Cited by 35 · see citing works

Neuregulin Autocrine Signaling Promotes Self-Renewal of Breast Tumor-Initiating Cells by Triggering HER2/HER3 Activation

Lee, C. Y.-F., Lin, Y., Bratman, S. V., Feng, W., Kuo, A. H., Scheeren, F. A., Engreitz, J., Varma, S., West, R. B., & Diehn, M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1055 · Cited by 34 · see citing works

HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer

Majumder, A. (2023) · Cells · doi:10.3390/cells12212517 · Cited by 34 · see citing works

Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts

Berdiel‐Acer, M., Maia, A. R. R., Hristova, Z., Borgoni, S., Vetter, M., Burmester, S., Becki, C., Michels, B. E., Abnaof, K., Binenbaum, I., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01719-3 · Cited by 32 · see citing works

Synthetic Modular Antibody Construction by Using the SpyTag/SpyCatcher Protein‐Ligase System

Alam, M. K., Gonzalez, C., Hill, W., El‐Sayed, A., Fonge, H., Barreto, K., & Geyer, C. R. (2017) · ChemBioChem · doi:10.1002/cbic.201700411 · Cited by 31 · see citing works

Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC

Zhang, K., Jones, L., Lim, S., Maher, C. A., Adkins, D. R., Lewis, J. S., Kimple, R. J., Fertig, E. J., Chung, C. H., Herrlich, A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2423 · Cited by 30 · see citing works

A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response

Xiao, Z., Carrasco, R. A., Schifferli, K. P., Kinneer, K., Tammali, R., Chen, H., Rothstein, R., Wetzel, L. K., Yang, C., Chowdhury, P. S., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0555 · Cited by 29 · see citing works

Targeted therapies in breast cancer

WICKI, A. N., & Rochlitz, C. F. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13550 · Cited by 28 · see citing works

NRG1 fusions in breast cancer

Howarth, K., Mirza, T., Cooke, S. L., Chin, S., Pole, J. C. M., Turro, E., Eldridge, M., García, R. M., Rueda, O. M., Boursnell, C., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-020-01377-5 · Cited by 28 · see citing works

A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem–Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy

Luraghi, P., Bigatto, V., Cipriano, É., Reato, G., Orzan, F., Sassi, F. P., Bacco, F. D., Isella, C., Bellomo, S. E., Médico, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2151 · Cited by 28 · see citing works

Targeting autocrine HB-EGF signaling with specific ADAM12 inhibition using recombinant ADAM12 prodomain

Miller, M. A., Moss, M. L., Powell, G., Petrovich, R. M., Edwards, L. L., Meyer, A. S., Griffith, L. G., & Lauffenburger, D. A. (2015) · Scientific Reports · doi:10.1038/srep15150 · Cited by 27 · see citing works

ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC

Alvarado, D., Ligon, G. F., Lillquist, J. S., Seibel, S. B., Wallweber, G. J., Neumeister, V. M., Rimm, D. L., McMahon, G., & LaVallee, T. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181356 · Cited by 26 · see citing works

Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity

Wuellner, U., Klupsch, K., Buller, F., Attinger-Toller, I., Santimaria, R., Zbinden, I., Henne, P., Grabulovski, D., Bertschinger, J., & Brack, S. (2015) · Antibodies · doi:10.3390/antib4040426 · Cited by 25 · see citing works

The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer

Wang, Q., Zhang, X., Shen, E., Gao, J., Cao, F., Wang, X., Li, Y., Tian, T., Wang, J., Chen, Z., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.06.005 · Cited by 25 · see citing works

Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer

Mok, T. S. K., Ladrera, G., Srimuninnimit, V., Sriuranpong, V., Yu, C., Thongprasert, S., Sandoval-Tan, J., Lee, J. S., Fuerte, F., Shames, D. S., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.04.023 · Cited by 24 · see citing works

ErbB3–ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas

Capparelli, C., Rosenbaum, S. R., Berman-Booty, L. D., Salhi, A., Gaborit, N., Zhan, T., Chervoneva, I., Roszik, J., Woodman, S. E., Davies, M. A., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2959 · Cited by 24 · see citing works

JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2–Targeted Therapies

Manole, S., Richards, E. J., & Meyer, A. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0123 · Cited by 25 · see citing works

Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor

Zuo, B., Yan, B., Zheng, G., Xi, W., Zhang, X., Yang, A., & Jia, L. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2089-5 · Cited by 24 · see citing works

ErbB3 upregulation by the HNSCC 3D microenvironment modulates cell survival and growth

Humtsoe, J. O., Pham, E., Louie, R. J., Chan, D. A., & Kramer, R. H. (2015) · Oncogene · doi:10.1038/onc.2015.220 · Cited by 24 · see citing works

A novel synthetic trivalent single chain variable fragment (tri-scFv) construction platform based on the SpyTag/SpyCatcher protein ligase system

Alam, M. K., Brabant, M., Solomon, V. R., Barreto, K., Fonge, H., & Geyer, C. R. (2018) · BMC Biotechnology · doi:10.1186/s12896-018-0466-6 · Cited by 23 · see citing works

ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor

Juliachs, M., Castillo, W., Vidal, A., Piulats, J. M., del Muro, X. G., Condom, E., Hernández‐Losa, J., Teixidó, C., Pandiella, A., Graupera, M., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28009 · Cited by 21 · see citing works

Identification of mTORC2 as a Necessary Component of HRG/ErbB2-Dependent Cellular Transformation

Lin, M.-C. J., Rojas, K. S., Cerione, R. A., & Wilson, K. F. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0555 · Cited by 19 · see citing works

HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285

Takagi, S., Banno, H., Hayashi, A., Tamura, T., Ishikawa, T., & Ohta, Y. (2014) · Oncoscience · doi:10.18632/oncoscience.23 · Cited by 19 · see citing works

Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer

Zhang, S., Mukherjee, S., Fan, X., Salameh, A., Mujoo, K., Huang, Z., Li, L., Salazar, G. T., Zhang, N., & An, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.11613 · Cited by 18 · see citing works

Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue

Flågeng, M. H., Knappskog, S., Haynes, B. P., Lønning, P. E., & Mellgren, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074618 · Cited by 18 · see citing works

The expression and localization of neuregulin-1 (Nrg1) in the gastrointestinal system of the rhesus monkey

Zhao, W. (2013) · Folia Histochemica et Cytobiologica · doi:10.5603/fhc.2013.006 · Cited by 18 · see citing works

Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas

Roller, D. G., Capaldo, B. J., Bekiranov, S., Mackey, A. J., Conaway, M. R., Petricoin, E. F., Gioeli, D. G., & Weber, M. J. (2015) · Oncotarget · doi:10.18632/oncotarget.6548 · Cited by 18 · see citing works

Heregulin induces resistance to lapatinib‐mediated growth inhibition of HER 2‐amplified cancer cells

Sato, Y., Yashiro, M., & Takakura, N. (2013) · Cancer Science · doi:10.1111/cas.12290 · Cited by 40 · see citing works

Abstract 3627: Inhibition of HER family kinase signaling and tumor cell proliferation in non-EGFR and non-HER2 positive cell lines by lapatinib

Greger, J., Shi, H., Liu, L., & Gilmer, T. M. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-3627

AMPK activation attenuates HER3 upregulation and Neuregulin-Mediated rescue of cell proliferation in HER2-Overexpressing breast cancer cell lines exposed to lapatinib

Buccinnà, B., Ramondetti, C., & Piccinini, M. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115228 · Cited by 8 · see citing works

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer

Leung, W.-Y., Roxanis, I., Sheldon, H., Buffa, F. M., Li, J., Harris, A. L., & Kong, A. H. (2015) · Oncotarget · doi:10.18632/oncotarget.3296 · Cited by 43 · see citing works

Neuregulin Autocrine Signaling Promotes Self-Renewal of Breast Tumor-Initiating Cells by Triggering HER2/HER3 Activation

Lee, C. Y.-F., Lin, Y., Bratman, S. V., Feng, W., Kuo, A. H., Scheeren, F. A., Engreitz, J., Varma, S., West, R. B., & Diehn, M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1055 · Cited by 34 · see citing works